Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Dupilumab effects on aspirin intolerance in N-ERD
2024-520082-31-01Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dupilumab in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD), sponsored by Medical University of Vienna. Primary endpoint: Tolerated aspirin dose levels. Started Sep 2025; status: completed.
02
Drugs
03
Conditions
nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD)
Beyond the preview
Go deeper on 2024-520082-31-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520082-31-01.